- Earlier this month, Vaxcyte announced it had fully enrolled its OPUS-1 and OPUS-2 Phase 3 trials of VAX-31, a 31-valent pneumococcal conjugate vaccine for adults, and recently published positive Phase 1/2 VAX-31 data in The Lancet Infectious Diseases.
- These milestones, together with FDA-aligned Phase 3 designs intended to support a future Biologics License Application, underscore VAX-31’s potential to broaden pneumococcal disease coverage versus existing adult vaccines.
- We’ll now examine how completion of enrollment in the pivotal OPUS-1 Phase 3 trial could influence Vaxcyte’s investment narrative and outlook.
This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.
Vaxcyte Investment Narrative Recap
To own Vaxcyte, you have to believe VAX-31 can translate its broad serotype coverage into real-world adoption while the company funds an expensive, pre revenue pipeline. Completion of enrollment in OPUS-1 and OPUS-2 clears a key operational hurdle and starts the clock toward late 2026 data, which now looks like the central near-term catalyst. The biggest risk remains that pivotal results or future guideline decisions do not support the usage levels needed to justify today’s R&D and manufacturing spend.
The most relevant recent update is Vaxcyte’s March publication of positive adult Phase 1/2 VAX-31 data in The Lancet Infectious Diseases. Those results, showing VAX-31 was observed to be well tolerated with robust immune responses versus Prevnar 20, are the foundation for the OPUS Phase 3 program that has just fully enrolled. Together, they frame how much is riding on the upcoming OPUS readouts to support a future BLA package and eventual vaccination recommendations.
Yet against this promising setup, investors should also understand the risk that if OPUS-1 data fall short on key serotypes or safety signals emerge...
Read the full narrative on Vaxcyte (it's free!)
Vaxcyte's narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies an earnings increase of about $794.7 million from -$766.6 million today.
Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 105% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already penciling in roughly US$424,000,000 of revenue by 2029, so if OPUS-1 or OPUS-2 data diverge from that bullish view, your own take on Vaxcyte’s upside and risk profile may end up very different.
Explore 4 other fair value estimates on Vaxcyte - why the stock might be worth less than half the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Vaxcyte research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- Our free Vaxcyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.
Looking For Alternative Opportunities?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com